Stock Ratings / Consumer Staples / GRDN / financials

CVS (61) YI (42) PETS (26) RDGT (43) ⌘ Pro Terminal →

Guardian Pharmacy Services Inc. (Class A) (GRDN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$40.45 +0.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Guardian Pharmacy Services Inc. (Class A) (GRDN) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRDN)Realized 20D OHLCV Swing Band: ±7.4%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How GRDN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$100.3M (6.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $1.23B

FY25

Rev $1.45B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.45B	20.2%	5%	$49.2M	$100.3M	37.7%
FY 2024	$1.23B	19.9%	-5.1%	-$110.0M	$58.0M	-34.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRDN)

✓Walkthrough of GRDN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.03%🛡️ HOLDING TREND SUPPORT

2026-10-30O $40.98H $41.37L $40.26C $40.45VOL 319.0K

RES: $49.88SUP: $39.08SMA50: $41.05SMA200: $38.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRDN Butterfly Map → + Track GRDN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

37.5%/yr Implied 5Y Growth

vs. +17.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRDN)

Consumer Staples Rank #4 of 146 ⚔️ CVS vs GRDN Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (GRDN vs. CVS, YI, PETS, RDGT)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, Guardian Pharmacy Services Inc. (Class A) (GRDN) ranks #4 by composite RQD confidence (77/100, grade B+) and #53 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRDN ACTIVE Guardian Pharmacy Services Inc. (Class A)	B+	77/100	52.1x	20.2%	37.7%	+0.30%	$2.56B	Benchmark Subject
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	+0.42%	$115.53B	/cvs-vs-grdn →
YI 111 Inc.	D-	42/100	—	5.8%	-20.5%	+0.34%	$26.2M	/yi-vs-grdn →
PETS PetMed Express Inc.	E	26/100	—	28.1%	-35.0%	-0.84%	$25.6M	/pets-vs-grdn →
RDGT Ridgetech Inc.	D-	43/100	—	3.6%	—	-2.45%	$3.0M	/rdgt-vs-grdn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802255

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardian Pharmacy Services Inc. (Class A) (GRDN) reported GAAP revenue of $1.45B (+17.9% vs. FY2024 revenue of $1.23B ) , GAAP net income of $49.2M, operating cash flow of $100.3M, and free cash flow of $100.3M (+73.0% YoY). On the balance sheet, GRDN closed FY2025 with $412.7M in total assets against $0 in total debt (Altman Z-Score: 12.39, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.45B	$49.2M	$100.3M	$100.3M	$412.7M	—
FY2024 (FY)	2024-12-31	$1.23B	-$110.0M	$58.0M	$58.0M	$320.8M	—

3. GRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $40.45 (+0.30% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #4 in composite RQD confidence.

How does GRDN compare to CVS and YI in the Consumer Staples sector?

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B+ (77/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRDN?

Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRDN trading relative to its 50-day, 200-day, and 52-week technical levels?

GRDN last traded at $40.45 (+0.30% on volume of 208,031 shares), positioning the stock -1.46% below its 50-day simple moving average ($41.05) and +6.22% above its 200-day simple moving average ($38.08). Across its 52-week range of $26.34 to $48.33, GRDN sits at the 64.2% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($37.46 to $43.44).